YD Bio

YD Bio Current Assets

The Current Assets of YD Bio (YDES) as of Oct 16, 2026 is 8.96 M USD. In the previous year, Current Assets was 3.47 M USD — a change of 158.31% (higher).

Current Assets

8.96 MUSD

YoY

158.31%

Last updated:

Current Assets of YD Bio is 2025 8.96 M USD. Current Assets of YD Bio was 2024 3.47 M USD. It decreases by 158.31% higher compared to the previous year.

The YD Bio Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2020
830,767.00 USD
Jan 1, 2021
129,560.00 USD
Jan 1, 2022
222,132.00 USD
Jan 1, 2023
271,790.00 USD
Jan 1, 2024
3.47 M USD
Jan 1, 2025
8.96 M USD
The YD Bio Current Assets history
YEARCurrent AssetsYoY
8.96 MUSD+158.31%
3.47 MUSD+1,175.94%
271,790.00USD+22.36%
222,132.00USD+71.45%
129,560.00USD-84.40%
830,767.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

YD Bio Stock analysis

What does YD Bio do? YD Bio Ltd is a company based in Taipei City, Taiwan, with its headquarters located in Taipei City. The company is set to go public on August 29, 2025, under the ticker symbol YDES and ISIN KYG983011076. YD Bio Ltd focuses on developing innovative solutions in the healthcare sector, particularly in early cancer detection and next-generation cell therapies. The company's core activities include creating non-invasive cancer detection tools for early diagnosis and monitoring, as well as developing ophthalmologic products for dry eye conditions. Additionally, YD Bio Ltd is engaged in exosome-based therapeutics designed to address complex diseases. The company aims to enhance patient outcomes and quality of life through the integration of advanced scientific research with practical, accessible healthcare solutions. YD Bio Ltd operates within the healthcare industry, though specific sector and industry classifications are not provided. The company's website is http://ir.ydesgroup.com/, where further information about its operations and future plans can be found. As a Taiwan-based entity, YD Bio Ltd contributes to the biotechnology and medical innovation landscape in the region. The company's IPO date is scheduled for 2025, indicating its readiness to expand its market presence and potentially scale its operations. YD Bio Ltd's mission centers on pioneering transformative healthcare solutions that improve and extend patient lives. YD Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about YD Bio stock

Current Assets of YD Bio is 8.96 M USD in 2025.

Current Assets of YD Bio changed from 3.47 M USD to 8.96 M USD, representing a 158.31% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Assets YD Bio since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's YD Bio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — YD Bio

All Key Metrics — YD Bio